Table 5. Three-piece IPP implantation surgery results*.
| Author | Study period | Devices | Patients | Mean follow up | Infection | Mech. dysfunction | Explants | Erosion | EDITS score | IIEF | General patient satisfaction | Overall device survival |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chung et al. (39), 2013 | 2006–2010 | AMS 700 CX | 88 | 40.6 months | 3 (2%) across both models | 7 (5.1%) across both models | 3 (2%) across both models | N/A | N/A | N/A | 86% | 91% (700CX) and 87% (Titan) 5 years est. |
| Coloplast Titan | 50 | 35.4 months | 90% | |||||||||
| Vitarelli et al. (51), 2013 | 1997–2010 | AMS 700 CX/CXR | 80 | 68.7 months | 2 (2.5%) | 10 (12.5%) | 13 (16.25%) | 3 (3.75%) | 73.11 | 21.46 | 87.7% | 91.9% (4 years); 77.6% (10 years) |
| Brinkman et al. (96), 2005 | 1992–1998 | AMS 700 Series; Mentor Alpha-1; Mentor Alpha NB | 12: AMS; 187: Mentor | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 69.3% across all models | N/A |
| Dhar et al. (97), 2006 | 1986–2004 | AMS 700 CX/CXM | 380 | 7.6 years | 8 (2%) | 39 (10.3%) | N/A | 8 (2%) | N/A | N/A | N/A | 74.9% (10 years est.) |
| Enemchukwu et al. (98), 2013 | 1997–2008 | AMS 700 CX | 39,443 | 7 years | N/A | 5,981 (10.9%) | N/A | N/A | N/A | N/A | N/A | 87% avg. (7 years) |
| AMS 700 LGX | 15,570 | |||||||||||
| Kim et al. (99), 2010 | 2001–2009 | AMS 700 CXM | 383 | 113 months | 8 | 82 (20.6%) | N/A | 3 (0.7%) | N/A | N/A | N/A | 93.2% (5 years); 78.2% (10 years) |
| AMS 700 CX | 14 | |||||||||||
| Lindeborg et al. (100), 2014 | 2008–2011 | Coloplast Titan | 33 | 16 months | 1 (3%) | 3 (9%) | 1 (3%) | N/A | 85% | N/A | N/A | 97% at follow-up |
| Negro et al. (101), 2016 | 2009–2012 | AMS LGX | 36 | 6 months | 0 | 0 | 0 | 0 | 77.8 mean at 12 months | 8.3 mean at 12 months | N/A | 100% at 6 months |
| Nehra et al. (102), 2012 | 2001–2007 | AMS 700 M/R-coated vs. non-M/R models | 9,300 (M/R) vs. 1,764 (non-M/R) | 34.4 (M/R) vs. 53.9 months (non-M/R) | 233 (2.5%) vs. 65 (3.7%) | 177 (1.6%) across all models | N/A | 211 (2%) across all models | N/A | N/A | N/A | 76.% (10 years) vs. 71.0% (10 years) |
| Ohl et al. (103), 2012 | 2007–2009 | Titan OTR | 113 | 6 months | 4 (3.5%) | 2 (1.8%) | 5 (4.3%) | 1 (0.9%) | N/A | N/A | 90% at 12 months. | 96% at 12 months |
| Serefoglu et al. (104), 2012 | 2000–2011 | Titan | 29,360 | 11 years | 1.4% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Song et al. (105), 2013 | 2000–2011 | AMS 700 CXM/CXR | 179 | 68.3 months | 1 (0.6%) | 4 (2%) | 1 (0.6%) | 1 (0.6%) | N/A | 20.2 | 89% | Not evaluated |
| Thomas et al. (106), 2011 | 1984–2007 | AMS 700 Series | 38 | 8.4 years | 2 (3.5%) | 15 (25%) | N/A | 4 (7.1%) | N/A | N/A | 65% | 81.6% 50 months |
| Wilson et al. (107), 2007 | N/A (prospective study) | AMS 700 Series; Mentor Alpha 1; Mentor Alpha 1 NB | 2,384 | N/A | 7% (by 10 years) | 20.6% (by 10 years) | N/A | N/A | N/A | N/A | 98.1% 10 years est. | 68.5% revision free 10 years |
| Rigicona | 2019–2020 | Infla10 | 400 | N/A | 4 (1.0%) | 2 (0.5%) | N/A | 1 (0.3%) | N/A | N/A | N/A | 97.7% (unspecified) |
*, table includes results from AMS and Coloplast prosthesis models published since 2006; a, data directly provided by Rigicon. AMS, American Medical Systems; N/A, not applicable or directly provided/analyzed; CX, controlled expansion; OTR, One-Touch release; CXM, controlled expansion module; CXR, controlled expansion restricted; LGX, length and girth expansion; M/R, minocycline/rifampin; NB, narrow base; est, estimate.